Trials / Completed
CompletedNCT03288974
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 397 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
PMS period: 09Jun2017 \~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib The primary objective of this Drug Use Examination (DUE) is to evaluate safety of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea. The secondary objective of this DUE is to evaluate effectiveness of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POMALYST® (Pomalidomide) | The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle |
Timeline
- Start date
- 2017-12-28
- Primary completion
- 2023-11-16
- Completion
- 2023-11-16
- First posted
- 2017-09-20
- Last updated
- 2025-04-15
Locations
33 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03288974. Inclusion in this directory is not an endorsement.